The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial.
 
Zhi-Ming Shao
No Relationships to Disclose
 
Jihui Hao
No Relationships to Disclose
 
Shui Wang
No Relationships to Disclose
 
Qingyuan Zhang
No Relationships to Disclose
 
Yuanting Gu
No Relationships to Disclose
 
Fuguo Tian
No Relationships to Disclose
 
Shouman Wang
No Relationships to Disclose
 
Quchang Ouyang
No Relationships to Disclose
 
Longzhen Zhang
No Relationships to Disclose
 
Yunjiang Liu
No Relationships to Disclose
 
Jing Cheng
No Relationships to Disclose
 
Shundong Cang
No Relationships to Disclose
 
Zhenzhen Liu
No Relationships to Disclose
 
Chunsen Xu
No Relationships to Disclose
 
Jianyun Nie
No Relationships to Disclose
 
Ye Lv
No Relationships to Disclose
 
Jun Qian
No Relationships to Disclose
 
Ting Wang
No Relationships to Disclose
 
Mengzhu Yu
Employment - Jiangsu Hengrui Pharmaceuticals
 
Fei Wu
Employment - Jiangsu Hengrui Pharmaceuticals